Pursuit Wealth Management LLC Purchases New Position in Merck & Co., Inc. $MRK

Pursuit Wealth Management LLC bought a new position in Merck & Co., Inc. (NYSE:MRK) during the 4th quarter, Holdings Channel reports. The firm bought 4,286 shares of the company’s stock, valued at approximately $451,000.

Several other institutional investors have also recently bought and sold shares of the business. DLD Asset Management LP raised its holdings in shares of Merck & Co., Inc. by 30.1% in the third quarter. DLD Asset Management LP now owns 47,500,000 shares of the company’s stock valued at $3,986,675,000 after buying an additional 11,000,000 shares during the last quarter. Assenagon Asset Management S.A. increased its holdings in shares of Merck & Co., Inc. by 192.7% in the third quarter. Assenagon Asset Management S.A. now owns 5,496,664 shares of the company’s stock valued at $461,335,000 after purchasing an additional 3,618,532 shares in the last quarter. Invesco Ltd. raised its position in Merck & Co., Inc. by 16.6% in the 3rd quarter. Invesco Ltd. now owns 19,844,936 shares of the company’s stock worth $1,665,585,000 after purchasing an additional 2,821,766 shares during the last quarter. Ameriprise Financial Inc. boosted its position in Merck & Co., Inc. by 20.7% in the 3rd quarter. Ameriprise Financial Inc. now owns 15,933,909 shares of the company’s stock valued at $1,336,877,000 after buying an additional 2,735,459 shares during the last quarter. Finally, Van ECK Associates Corp increased its stake in shares of Merck & Co., Inc. by 61.6% in the 3rd quarter. Van ECK Associates Corp now owns 5,325,033 shares of the company’s stock valued at $446,930,000 after buying an additional 2,029,342 shares during the period. Institutional investors own 76.07% of the company’s stock.

Insider Activity

In other news, EVP David Michael Williams sold 5,000 shares of the stock in a transaction dated Friday, February 6th. The shares were sold at an average price of $121.91, for a total transaction of $609,550.00. Following the completion of the transaction, the executive vice president directly owned 30,838 shares in the company, valued at $3,759,460.58. This represents a 13.95% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CMO Chirfi Guindo sold 10,000 shares of the firm’s stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $118.41, for a total value of $1,184,100.00. Following the completion of the transaction, the chief marketing officer owned 70,615 shares of the company’s stock, valued at $8,361,522.15. The trade was a 12.40% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 320,176 shares of company stock worth $38,281,735. 0.13% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several equities analysts recently issued reports on MRK shares. Wells Fargo & Company raised their price target on Merck & Co., Inc. from $135.00 to $150.00 and gave the company an “overweight” rating in a report on Thursday, March 12th. Deutsche Bank Aktiengesellschaft raised shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating and set a $150.00 target price on the stock in a research note on Friday, February 13th. TD Cowen boosted their price target on shares of Merck & Co., Inc. from $100.00 to $120.00 and gave the stock a “hold” rating in a research note on Tuesday, January 20th. Wolfe Research upgraded Merck & Co., Inc. from a “peer perform” rating to an “outperform” rating and set a $135.00 price objective for the company in a report on Thursday, January 8th. Finally, Guggenheim upped their price target on Merck & Co., Inc. from $122.00 to $140.00 and gave the company a “buy” rating in a research note on Friday, February 6th. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and seven have assigned a Hold rating to the company. According to MarketBeat.com, Merck & Co., Inc. has an average rating of “Moderate Buy” and an average price target of $128.47.

Merck & Co., Inc. Stock Down 1.6%

Merck & Co., Inc. stock opened at $118.07 on Thursday. Merck & Co., Inc. has a twelve month low of $73.31 and a twelve month high of $125.14. The company has a quick ratio of 1.30, a current ratio of 1.54 and a debt-to-equity ratio of 0.89. The company has a 50 day moving average of $119.26 and a 200-day moving average of $105.51. The stock has a market capitalization of $291.62 billion, a PE ratio of 16.22, a price-to-earnings-growth ratio of 2.41 and a beta of 0.26.

Merck & Co., Inc. (NYSE:MRK) last announced its earnings results on Tuesday, February 3rd. The company reported $2.04 earnings per share for the quarter, topping analysts’ consensus estimates of $2.01 by $0.03. The firm had revenue of $16.40 billion during the quarter, compared to analyst estimates of $16.19 billion. Merck & Co., Inc. had a net margin of 28.08% and a return on equity of 44.57%. The company’s revenue for the quarter was up 5.0% compared to the same quarter last year. During the same period in the prior year, the business earned $1.72 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. On average, equities research analysts anticipate that Merck & Co., Inc. will post 9.01 EPS for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, April 7th. Shareholders of record on Monday, March 16th were paid a $0.85 dividend. This represents a $3.40 annualized dividend and a yield of 2.9%. The ex-dividend date was Monday, March 16th. Merck & Co., Inc.’s payout ratio is presently 46.70%.

Merck & Co., Inc. News Roundup

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: FDA grants priority review to Merck and Daiichi’s BLA for ifinatamab deruxtecan in extensive-stage small cell lung cancer — this accelerates the regulatory timeline for a potentially material oncology asset and could add to future revenue if approved. MRK, Daiichi’s BLA for ADC Drug Gets FDA Priority Tag in Lung Cancer
• Positive Sentiment: UBS raised its price target on MRK to $145, signaling bullish analyst sentiment and providing support for longer‑term upside relative to current levels. UBS Group Boosts Merck & Co., Inc. (NYSE:MRK) Price Target to $145.00
• Positive Sentiment: Keytruda remains the primary growth driver (over half of pharma sales); analysts will be watching Q1 results and guidance for continued uptake from new indications — a clean print would likely stabilize the stock. Will Keytruda Continue to Aid Merck’s Top Line in Q1 Earnings?
• Neutral Sentiment: Options/technical coverage: a retail/options piece outlines a bullish diagonal trade targeting $130 by mid‑June — this reflects trader optimism but is speculative and not company‑fundamental. This Merck (MRK) stock bullish diagonal trade targets a price of $130 by June 18
• Neutral Sentiment: Industry tailwinds in animal health highlighted in a market report (Merck’s animal-health unit participates in this market), a long‑term positive structural theme but not an immediate catalyst. Animal Health Market Intelligence Report 2026-2034
• Neutral Sentiment: Coverage about Merck KGaA (XTRA:MRK) appears in the news stream — note this is a different company (German Merck), which can cause ticker confusion among retail investors but does not affect Merck & Co.’s fundamentals. Assessing Merck KGaA (XTRA:MRK) Valuation After Mixed Recent Share Performance And Healthcare Pipeline Developments
• Negative Sentiment: Media scrutiny of Merck’s patent strategies and pricing for Keytruda (USAToday feature) can increase regulatory and reputational risk; that scrutiny can weigh on sentiment and prompt selling or political/regulatory pressure. How Merck keeps prices for its blockbuster cancer drug sky high
• Negative Sentiment: Near‑term price weakness / market reaction: recent intraday moves show MRK underperforming broader indices, reflecting profit‑taking and caution ahead of earnings/updates. Merck (MRK) Stock Sinks As Market Gains: Here’s Why

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.